claim: first clinical use of lenzilumab to neutralize gm-csf in patients with severe and critical covid-19 pneumonia
evidence_1: methods hospitalized patients with covid-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an emergency single-use ind application.", "conclusions in high-risk covid-19 patients with severe and critical pneumonia, gm-csf neutralization with lenzilumab was safe and associated with improved clinical outcomes, oxygen requirement, and cytokine storm.", "with this rationale, we used lenzilumab, an anti-human gm-csf monoclonal antibody, to treat patients with severe and critical covid-19 pneumonia.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "lenzilumab was supplied by humanigen, inc. for the compassionate use treatment of covid-19 subjects by investigators at the mayo clinics.")